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Abstract Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation that is not fully 
reversible, with disabling symptoms including chronic cough and dyspnoea.Although a number of studies in the U.S.A. have 
assessed the impact of COPD on the healthcare system and society, data on healthcare resource utilization (particularly 
outpatient services and medication use) in patients with mild to moderate COPD, or patients who meet symptom criteria 
for COPD but have not received this diagnosis, are limited or unavailable.To fill gaps in current knowledge about the impact 
of this disease, an economic analysis was conducted on the data collected from patients enrolled in the U.S.A. sample of 
Confronting COPD in North America and Europe, the first large-scale international survey of the burden of the disease.The 
annual cost of healthcare resource utilization was estimated at US$4l 19 per patient with COPD, with indirect (non- 
medical care) costs amounting to US$ I527 per patientThe annual estimated societal cost was therefore US$5646 per 
patientThe majority of disease costs in the survey were associated with inpatient hospitalizations (US$289 I).The results 
of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute 
exacerbations could substantially decrease the costs associated with this disease. 
0 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
progressive disorder of airflow limitation that is not fully 
reversible, with disabling symptoms including chronic 
cough and dyspnoea. In the U.S.A. in 2000, approximately 
IO million adults responding to the National Health 
Interview Survey reported a diagnosis of COPD (I).The 
self-reported prevalence rate of physician-diagnosed 
chronic bronchitis and emphysema was estimated at 
60 per 1000 of the population, with a higher proportion 
of women affected than men (45.5 per 1000 versus 73.2 
per IO00 people). However,  data from the third National 
Health and Nutrition Examination Survey (NHANES Ill) 
showed that 24 million adults (I 3.5 million men, and IO.5 
million women) had mild or moderate obstructive lung 
disease, suggesting that COPD is significantly under- 
diagnosed in this country (I). 
COPD is a serious health problem in the U.S.A. 
Mortality from COPD increased by 40% between 1979 
and 1998, rising from 14.0 to 19.9 deaths per IO0 000 of 
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the general population, and becoming the fourth leading 
cause of death (exceeded only by heart attack, cancer and 
stroke) (2). COPD-related illness places a significant 
burden on the healthcare system, with an estimated direct 
cost of US$ I522 per patient per year, three times the per 
patient cost of asthma (3). The burden of COPD is 
particularly high in secondary care, with over 660 000 
hospital discharges for COPD recorded in 1998 (4).The 
annual cost of hospital care for COPD in the U.S.A. was 
estimated at US$7.3 billion in 2000,40% of the total direct 
(medical care) cost of the disease (US$l8.0 billion) (5). 
Much of the cost of hospital care for COPD arises from 
the management of acute exacerbations of the disease, 
with inpatient stays being the primary cost driver (6). 
The cost of COPD in the U.S.A. has been shown to 
rise with disease severity.The cost of treating a patient 
with severe COPD has been estimated at US$ IO8 I2 per 
year, compared with US$ I681 for a patient with mild 
disease and US!$5037 for a patient with moderate 
disease (7).The direct cost of COPD also increases with 
the duration of smoking history; estimates of direct 
medical costs for I.3 million patients with COPD from 
the 1987 US National Medical Expenditure survey 
showed that healthcare expenditures were higher in 
COPD patients with 250 pack-year smoking history 
(US$7212 per patient per year) than in COPD patients 
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who had smoked for <SO pack years (US$6642), or had 
never smoked (US$63 17) (8). 
In addition to direct costs, COPD has been shown to 
have a significant impact on non-medical costs (e.g. 
workplace costs) in the U.S.A. The total cost of lost 
productivity due to COPD in this country was estimated 
at US$I4. I billion in 2002, bringing the total societal cost 
of the disease to an estimated US$32. I billion (5). 
Although a number of studies in the U.S.A. have assessed 
the impact of COPD on the healthcare system and society, 
most studies have been based on patients diagnosed with 
COPD (in particular, those with severe disease), or specific 
groups of patients receiving treatment under the provision 
of individual healthcare plans (9). Data on healthcare 
resource utilization (particularly outpatient services and 
medication use) in patients with mild to moderate COPD, 
or patients who meet symptom criteria for COPD but 
have not received this diagnosis, are limited or unavailable. 
To fill gaps in current knowledge about the impact of this 
disease, an economic analysis was conducted on data 
collected from patients in the U.S.A. responding to the 
Confronting COPD in North America and Europe survey, the 
first large-scale international survey of the burden of the 
disease. The survey included patients with physician 
diagnosed and undiagnosed COPD, and collected 
information on healthcare resource utilization and direct 
costs, as well as indirect costs resulting from COPD- 
related patient work absence. This paper reports the 
results of the economic analysis of the U.SA. data. Results 
from other countries participating in the survey are 
presented elsewhere (I O-l 5). 
METHODS 
Survey methods 
The methodology of the Confronting COPD survey is 
described in detail elsewhere (I 6-17). In summary, 
telephone interviews were conducted with 3265 
patients and 905 physicians from the U.S.A., Canada, 
France, Germany, Italy, the Netherlands, Spain and the 
U.K., to collect information about the country-specific 
burden of COPD. In all countries except Germany, 
quantitative measures of healthcare resource utilization 
and work loss were derived from responses to the 
patient questionnaire, and used to estimate the direct, 
indirect and societal per patient costs of COPD for the 
I -year period prior to the initiation of the survey.A sub- 
analysis was also conducted to investigate relationships 
between the COPD costs and self-reported disease 
severity, gender, smoking status, comorbidities and 
education level. 
Unit costs 
Unit costs used in the economic analysis of data from 
Confronting COPD survey in the U.S.A. are shown in 
Table I (7). Costs for time lost from work were applied 
to patients up to the mean age of retirement (62-O years 
for men and 61.4 years for women) (18). 
RESULTS 
Patient demographics 
The characteristics of the patient sample enrolled in the 
Confronting COPD survey in the U.S.A. are shown in 
Table 2. 
Patients ranged from 42-89 years of age, and 55.3% 
were female. All patients in the sample were current 
(42.7%) or former smokers (57.3%) and the mean 
smoking history for the patient sample was 52 pack years 
(range O-3 IO pack years); 9% of patients in the survey did 
not report having physician-diagnosed COPD, but 
reported chronic bronchitis as defined by persistent 
coughing with phlegm or sputum production for the last 
2 years or more. The majority of patients (70%) 
considered their condition to be mild or moderate at 
the time of the survey. Over half (57%) of the patients 
had serious or chronic health conditions other than 
COPD. The most commonly reported comorbidities 
were heart disease (I 5%) hypertension (I I %), arthritis 
(I I%) and diabetes (8%). 
Healthcare professional contacts and 
hospital visits 
Two-thirds (68%) of patients surveyed normally visited a 
primary care practitioner (PCP) for the management of 
their condition.The percentage of patients who reported 
scheduled and unscheduled contacts with healthcare 
professionals for COPD is shown in Fig. I. A mean of 
4.6 scheduled PCP visits per patient were reported 
during the year prior to the interview, and 8% of the 
total number of PCP visits were reported as 
unscheduled care visits (mean 0.4 I per patient) (Table 3). 
The maximum number of unscheduled visits by any one 
patient was IS. 
One-third (32%) of the patients with COPD in the 
U.S.A. sample were receiving treatment from a specialist 
(pulmonary specialist, allergist, cardiologist or other) in 
primary or secondary care. Unscheduled visits to a 
specialist were reported by only 4% of patients (Fig. I), 
but accounted for 13% of the total number of specialist 
contacts, with a mean of 0.27 unscheduled specialist 
visits per patient (Table 2). One-fifth (20%) of the 
patients contacted a pulmonary specialist at least three 
times in the year prior to the survey. 
One-third of patients enrolled in the Confronting 
COPD survey in the U.S.A. had been hospitalized at 
some time in their lives due to COPD. One in seven 
patients reported an inpatient stay during the I2 months 
prior to the survey (Fig. I), with a mean of 0.38 
hospitalizations per patient (Table 3). One-fifth (2 I %) of 
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FIGURE I. Percentage of patients reporting (2 I) category of healthcare resource use during the I2 months prior to the survey. 
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FIGURE 2. Percentage of patients reporting use of > I class of prescribed medication. 
patients reported a visit to the emergency room for the 
treatment of COPD (Table 3), with a mean of 0.52 visits 
per patient. 
Treatment for COPD 
Around two-thirds (67%) of patients in the U.S.A. sample 
were taking prescribed medication for the treatment of 
COPD. Short-acting &-agonists (44%) inhaled 
corticosteroids (3 I %) and anticholinergics (26%) were 
prescribed most frequently (Fig. 2). Two-fifths (40%) of 
patients had a nebulizer for the administration of 
bronchodilator medication. More than half of the 
patients had received antibiotics for respiratory 
infections (Table4). One-quarter (24%) of the patients 
had used home oxygen therapy for COPD in the last 
I2 months with total usage over the previous year 
estimated to be 34 620 days (72.58 days per patient). In 
addition, three-fifths (60.4%) had an influenza vaccination 
in the past year. 
Diagnostic tests and procedures 
In the U.S.A. sample, a mean of 2.3 diagnostic tests and 
procedures (chest radiography, electrocardiograph 
(ECG), computerized tomography (CT) scan, magnetic 
resonance imaging (MRI) scan, blood oxygen assessment) 
were conducted per patient (Fig. 3,Table 5).Two-thirds of 
patients reported at least one chest radiograph, and 
more than two-fifths of patients reported getting at least 
one ECG, or a blood oxygen level assessment with a 
finger stick test or hypodermic needle/syringe test. A 
quarter of patients reported having at least one CT or 
MRI scan. 
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FIGURE 3. Patients reporting at least one laboratory test for COPD during the I2 months prior to the survey. 
Work loss due to COPD 
One-third (34%) of patients reported that they were 
prevented from working because of their COPD. Almost 
one-fifth (I 8%) of patients were limited in their ability to 
work normally, and 6% of patients (n=25) missed time 
from work due to COPD. Over the previous year, the 
total number of work days lost by patients was estimated 
at 6838 days ( 18.7 days per patient of working age).Work 
loss among the caregivers of patients with COPD was 
reported by 7% of respondents, with a total of 54 days 
lost (mean of I -7 days per caregiver reporting work loss). 
Direct costs 
The annual cost of healthcare resource utilization was 
estimated at US$4 I 20 per patient with COPD.The highest 
per patient cost of any individual healthcare resource was 
For inpatient hospitalizations, which was estimated at 
US$2891 a00 and accounted for over 70% of the total 
direct costs of COPD.When the cost of emergency room 
visits and unscheduled contacts with a PCP or specialist 
was added to inpatient costs, the estimated cost of these 
unscheduled care visits accounted for 78% of the total per 
patient cost of COPD to the U.S.A. healthcare system 
(Fig. 4). It was estimated that less than 10% of direct per 
patient costs were for scheduled care visits, treatment for 
COPD (including regular prescribed medication use, 
courses of antibiotics, influenza vaccination and oxygen 
therapy), or laboratory tests. 
Table 6 provides a summary of the estimated per 
patient costs by healthcare resource measure.The mean 
cost of inpatient hospitalization (US$289 I, 
SD + US$I 3697) was over I2 times higher than the 
mean cost of PCP visits (US$225, SD & US$428) and 
I4 times higher than the mean cost of specialist contacts 
for COPD (US$204, SD f US$416). The cost of 
treatment for COPD was estimated at US$242 per 
patient (SD f US$56), with 59% of costs for antibiotics. 
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Use of regular prescription medication was associated 
with only one-fifth (22.2%) of the estimated treatment 
costs, and only I .3% of the estimated total direct cost of 
COPD per patient. 
Societal costs 
The indirect cost of COPD was calculated from work 
loss and was estimated at US$ I527 per patient. Adding 
this to the direct cost of the disease gave an estimated 
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FIGURE 5. Annual societal costs of COPD by disease severity 
societal cost of US$5646 (of which 73% was direct costs 
and 27% was indirect costs). 
costs by demographic category showed that the direct, 
indirect and societal costs of COPD per patient were 
particularly high in female patients, former smokers, 
Associations between costs and patient 
variables 
patients with comorbidities, and patients with no 
education beyond high school (Table 7). 
A sub-analysis of costs was conducted in patient groups 
stratified by disease severity, either self-perceived or 
DISCUSSION 
assessed in terms of scores on the Medical Research The Confronting COPD survey provides an estimate of 
Council Dyspnoea Scale (19) (score O-2: mild COPD, the impact of COPD, in terms of healthcare resource 
score 3-I: moderate COPD, score 5: severe COPD).The utilization and work loss.These estimates were used to 
results showed that severe COPD was associated with calculate the societal cost of the disease. Patients 
considerably higher annual societal costs per patient than enrolled in the study had been diagnosed with COPD, 
moderate or mild COPD (Fig. 5). Further analysis of chronic bronchitis or emphysema, or had symptoms 
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consistent with the chronic bronchitis (persistent cough 
or sputum production for at least 2years prior to the 
survey). 
The results from the U.S.A. sample showed that two- 
thirds of patients normally saw a primary care 
practitioner for the everyday management of their 
condition. Almost one-third of patients were receiving 
specialist care, the majority of which had seen a 
respiratory specialist a number of times in the previous 
year. One-third of patients had been hospitalized for 
COPD at sometime in their lives, and one-fifth of 
patients had visited the emergency room at least once 
in the last I2 months.The estimated annual direct cost 
of COPD was considerable, at over US$4 100 per 
patient. As well as having an impact on the healthcare 
system, COPD-related illness and disability prevented 
one-third of patients under retirement age from 
working, and 6% of patients missed time from work.The 
estimated indirect cost of patient work loss totalled 
US!$l527 per patient, over one-quarter of the societal 
costs of COPD. 
The majority (70%) of healthcare costs in the survey 
were associated with inpatient hospitalizations. Other 
forms of unscheduled care for COPD (emergency room 
visits, contacts with primary care practitioners or 
specialists) contributed another 8% to the direct cost of 
the disease. Unscheduled visits and hospitalizations may 
reflect poor symptom control, particularly the treatment 
of worsening symptoms during acute exacerbations. 
These results suggest that the burden of COPD on the 
healthcare system could be reduced by shifting the focus 
of care away from the acute management of symptom 
exacerbations, towards improving the long-term 
management of the disease in primary care, with the aim 
of preventing exacerbations and reducing the risk of 
COPD-related hospitalization. 
National and international treatment guidelines outline 
a number of goals for the treatment of COPD in primary 
care, including the prevention of exacerbations and 
controlling symptoms with appropriate medication. 
However, the results of this U.S.A. survey suggest that 
these goals are not being achieved in many patients. 
Although 9 I% of patients with COPD reported a 
physician diagnosis of the disease, one-third of patients 
were not receiving regular prescribed medication, and 
two-thirds of patients reported that their condition was 
only somewhat or poorly controlled. Over half of the 
patients had received antibiotics for respiratory 
infections in the previous year, which may suggest that 
exacerbations were a common occurrence.These results 
highlight the need for patients to receive interventions 
that can alleviate symptoms and prevent exacerbations, 
to reduce both morbidity and the direct costs associated 
with the disease. Bronchodilators are the mainstay of 
treatment for COPD, supported by evidence of 
improved lung function, symptoms and quality of life. 
However, bronchodilators are limited in their ability to 
reduce the frequency and severity of exacerbations, and 
reducing the risk of exacerbations may require the use of 
medications that act upon the underlying inflammatory 
processes of the COPD. Currently, the main strategy 
recommended by treatment guidelines for the 
prevention of COPD exacerbations is influenza 
vaccination, but this intervention was underutilized in the 
U.S.A. sample, with only 60% of patients in the survey 
reporting a vaccination in the previous year. Recent 
evidence suggests that the use of inhaled corticosteroids 
may also reduce the impact of exacerbations in patients 
with COPD, but only one-third of patients in the survey 
reported taking this class of medication. 
The direct, indirect and societal costs of COPD in the 
survey sample were particularly high in patients with 
severe COPD, which supports previous studies 
conducted in the U.S.A. (7-8). This suggests that 
interventions that could effectively delay the progression 
to severe COPD could reduce the costs of the disease. 
Encouraging patients to stop smoking in the early stages 
of COPD is considered to be the single most important 
intervention for reducing the long-term impact of the 
disease on the patient and society. In this survey, former 
smokers were more costly to the healthcare system and 
the economy than current smokers. However, this may 
reflect differences in disease severity and the impact of 
the ‘quitting ill’ effect, in which smokers quit upon 
developing disease symptoms or immediately after 
diagnosis of smoking-related diseases (20). 
The survey showed that patients with COPD and 
other serious or chronic conditions are more costly to 
the healthcare system and society than patients with 
COPD alone. This supports the results of previous 
studies, which have shown that a significant proportion of 
the direct cost of COPD in the U.S.A. is associated with 
patients who have comorbid illness (e.g. coronary heart 
disease, congestive heart failure, hypertension, or 
malignant disease), with costs rising with the number of 
comorbidities (8-9). For example, an analysis of data 
from patients enrolled in a health maintenance 
organization revealed that per patient cost of inpatient 
care for a COPD patient with comorbidity was more 
than twice as high as the cost of equivalent care for a 
patient with COPD alone (US$5093 versus US$2026) 
(9). Outpatient care and pharmacy costs were also 
higher in patients with comorbidity than controls 
(US$5042 versus US$3050 and US$ I545 versus US$739 
per patient, respectively).Therefore, reducing the number 
of comorbidities that a patient may develop could 
significantly alleviate the burden of COPD in the U.S.A. 
Smoking cessation is likely to have a role to play here, as 
in addition to delaying disease progression, this 
intervention reduces the risk of a patient developing 
conditions such as coronary artery disease and cancer 
(9). 
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CONCLUSION 
In the U.S.A., the yearly costs of COPD to the healthcare 
system and society are considerable, estimated from this 
survey to be over US45600 per patient.The majority of 
disease costs in the survey were associated with 
unscheduled care, specifically inpatient hospitalizations, 
suggesting that improving the long-term management of 
the disease in primary care could reduce the burden of 
disease. Improving disease management in the U.S.A. may 
require an increase in the availability and usage of 
interventions that can prevent exacerbations, reduce the 
risk of hospitalizations, improve symptom control, delay 
disease progression and reduce the risk of comorbidities 
in patients with COPD. 
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